Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women

American Journal of Obstetrics and Gynecology

Volumn 212, Issue 3, 2015, Pages 318.e1-318.e8

  Kaunitz, Andrew M ^a   Archer, David F ^b   Mishell, Daniel R ^c   Foegh, Marie ^d,e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Agile Therapeutics   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

combination oral contraceptive; contraceptive patch; obese; Ortho Evra; Twirla

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; LEVONORGESTREL; NORGESTREL;

ADOLESCENT; ADULT; APPLICATION SITE REACTION; ARTICLE; BREAST TENDERNESS; CONTRACEPTIVE PATCH; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OBESITY; OPEN STUDY; OVARY CYST; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SKIN MANIFESTATION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX DYSPLASIA; VEIN THROMBOSIS; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; OUTCOME ASSESSMENT; TRANSDERMAL PATCH; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; NORGESTREL; OBESITY; PATIENT OUTCOME ASSESSMENT; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84924763736     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2014.09.014     Document Type: Article

References (29)

1. D.B. Petitti Hormonal contraceptives and arterial thrombosis - not risk-free but safe enough N Engl J Med 366 2012 2316 2318
2. M.J. Rosenberg, M.S. Waugh, and T.E. Meehan Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation Contraception 51 1995 283 288
3. M. Rosenberg, and M.S. Waugh Causes and consequences of oral contraceptive noncompliance Am J Obstet Gynecol 180 Pt 2 1999 276 279
4. D.A. Hughes, A. Bagust, A. Haycox, and T. Walley The impact of non-compliance on the cost effectiveness of pharmaceuticals: a review of the literature Health Econ 10 2001 601 615
5. D.F. Archer, V. Cullins, G.W. Creasy, and A.C. Fisher The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy Contraception 69 2004 189 195
6. Ortho Evra [prescribing information] 2001 Ortho-McNeil Pharmaceuticals, Inc Raritan, NJ
7. Petition to ban ethinyl estradiol/norelgestromin (Ortho-Evra). Public Citizen [Web site]. Updated May 8, 2008. Available at: http://www.citizen.org/notmypatch. Accessed May 1, 2013.
8. Ortho Evra [prescribing information] 2011 Ortho-McNeil-Janssen Pharmaceuticals, Inc Raritan, NJ
9. O. Lidegaard, L.H. Nielsen, C.W. Skovlund, and E. Løkkegaard Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-2010 BMJ 344 2012 e2990
10. US Food and Drug Administration, Office of Surveillance and Epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. FDA, 2011. Available at: www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf. Accessed May 1, 2013.
11. US Food and Drug Administration Drug Safety Communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm299305. Accessed June 9, 2014.
12. J. Dinger, K. Bardenheuer, and K. Heinemann Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives Contraception 89 2014 253 263
13. E.R. Pomp, S. le Cessie, F.R. Rosendaal, and C.J. Doggen Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations Br J Haematol 139 2007 289 296
14. Society of Family Planning S. Higginbotham Contraceptive considerations in obese women: release date September 1, 2009, SFP Guideline 20091 Contraception 80 2009 583 590
15. F.Z. Stanczyk, A. Rubin, L. Flood, and M. Foegh Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinyl estradiol and levonorgestrel Horm Mol Biol Clin Invest 6 2011 231 240
16. D.F. Archer, F.Z. Stanczyk, A. Rubin, and M. Foegh Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity, and exercise Contraception 87 2013 212 219
17. A.M. Kaunitz, D. Portman, and C.L. Westhoff Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial Obstet Gynecol 123 2 Pt 1 2014 295 303
18. K.M. Flegal, M.D. Carroll, B.K. Kit, and C.L. Ogden Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 JAMA 307 2012 491 497
19. Agile Therapeutics. An open-label, randomized, phase 3 study of the contraceptive efficacy and safety of agile transdermal contraceptive delivery system (TCDS) in comparison to an oral contraceptive containing 150 mcg levonorgestrel and 30 mcg ethinyl estradiol. Available at: ClinicalTrials.gov [Web site]. Bethesda, MD. Available at: http://clinicaltrials.gov/ct2/show/NCT01236768. NLM identifier: NCT01236768. Accessed May 1, 2013.
20. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of obesity in the United States, 2009-2010 NCHS Data Brief 82 2012 1 8
21. M.C. Audet, M. Moreau, and W.D. Koltun Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial JAMA 285 2001 2347 2354
22. M.W. van den Heuvel, A.J. van Bragt, A.K. Alnabawy, and M.C. Kaptein Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive Contraception 72 2005 168 174
23. D.F. Archer, F.Z. Stanczyk, A. Rubin, and M. Foegh Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial Contraception 85 2012 595 601
24. D.J. Portman, A.M. Kaunitz, B. Howard, H. Weiss, J. Hsieh, and N. Ricciotti Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive Contraception 89 2014 299 306
25. C.L. Westhoff, A.T. Torgal, E.R. Mayeda, N. Shimoni, F.Z. Stanczyk, and M.C. Pike Predictors of noncompliance in an oral contraceptive clinical trial Contraception 85 2012 465 469
26. H.V. Joffe, and S.Z. Goldhaber Upper-extremity deep vein thrombosis Circulation 106 2002 1874 1880
27. S. Sidney, T.C. Cheetham, and F.A. Connell Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users Contraception 87 2013 93 100
28. E.G. Raymond, A.E. Burke, and E. Espey Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective Obstet Gynecol 119 2012 1039 1044
29. S.S. Jick, K.W. Hagberg, and J.A. Kaye Ortho Evra and venous thromboembolism: an update Contraception 81 2010 452 453